Psychobiotics Industry Analysis 2018-2022 & 2023-2028: Insights Into Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, and Other Applications – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The Global Psychobiotics Market Assessment 2018-2028 report has been added to ResearchAndMarkets.com’s offering.

Emergence of the Global Psychobiotics Market: A Transformative Journey (2024-2028)

The Global Psychobiotics market is on the brink of a remarkable journey between 2024 and 2028, fueled by the escalating concern over mental health issues. This growth trajectory is underscored by the pressing need to address stress, anxiety, sleep disorders, and other mental health challenges that have become pervasive in contemporary society. A pivotal milestone in this journey is the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) of 2019, which brought anxiety and depression disorders to the forefront.

These conditions ranked among the top 25 causes of global disease burden, impacting both genders across the globe. Despite considerable evidence-based interventions, there has been no decline in the global prevalence or burden of these disorders, intensifying the call for effective solutions. Moreover, the global pandemic triggered by COVID-19 and the subsequent worldwide lockdowns in 2020-2021 have amplified mental health struggles across diverse populations.

Addressing Anxiety and Depression Through Probiotics

The rise of probiotics as an avenue to address mood disorders, particularly anxiety and depression, marks a significant stride in mental health management. Probiotics, through their interaction with the microbial-gut-brain axis, offer a means to modulate mood and overall health. Anxiety and depression, both characterized by a gradual erosion of emotional well-being, share intricate connections. Persistent anxiety can escalate into severe depressive conditions if left unmanaged. Stress, arising from a variety of physically or emotionally taxing events, can evolve into anxiety when not adequately addressed.

Intriguingly, numerous studies highlight a nuanced interplay between anxiety and depression, exemplified by data showing that 28% of clinically anxious individuals concurrently experience depression. The gut microbiota’s active role in mood regulation further supports the potential of probiotics in diverse applications. Studies reveal correlations between specific bacteria variations and major depressive disorders. Probiotics’ ability to induce neurotransmitter production and modulate neurotransmitter receptors within the brain further underscore their influence on central nervous system activity. Additionally, they possess the capacity to mitigate inflammation by enhancing anti-inflammatory cytokines while diminishing pro-inflammatory agents.

An Escalating Prevalence of Mental Health Concerns

Depression and anxiety disorders, being among the most prevalent mental health issues, have assumed a critical global dimension. Depression, characterized by a sense of hopelessness, depleted mood, and diminished interest, along with anxiety, marked by excessive worry and physical manifestations, are rampant. According to the World Health Organization (WHO), anxiety disorders were prevalent in 3.6% of the population, and depression impacted 4.4% of the global populace in 2015.

The COVID-19 pandemic, with its unprecedented challenges, has exacerbated these concerns. A Lancet study revealed a staggering 25.6% global surge in anxiety disorders and a 27.6% increase in depressive conditions across both genders. Women bore a more pronounced impact, with a 29.8% surge in depression and 27.9% in anxiety compared to 21.7% in men.

Shaping Consumer Preferences and Market Dynamics

The burgeoning awareness of consumers, coupled with changing dietary preferences, has significantly influenced the trajectory of the psychobiotics market. Psychobiotics’ potential to not only enhance mental well-being but also contribute to improved digestion has struck a chord with health-conscious individuals. Furthermore, the ability of psychobiotics to cater to specific consumer needs, such as immune system support and gastrointestinal health, has intensified the demand. The Kerry Group’s global poll of 2019 revealed that 62% of health-conscious Americans were familiar with probiotics, and 32% had incorporated them into their routines over the past six months. A staggering 79% of respondents highlighted enhanced digestive health as the most desirable health benefit.

Innovation and Market Segmentation: A New Era

The trajectory of the Global Psychobiotics market hinges on innovation, a driving force behind diversifying product offerings and meeting evolving consumer needs. The market’s segmentation encompasses psychotropic agents, forms, and applications. Noteworthy psychobiotic bacteria, such as Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, and others, categorize psychobiotic agents. Market forms include powder, liquid/fluid, tablets, and more, while applications span stress management, mood enhancement, depression, anxiety, sleep disorders, and beyond.

Leading the Path Forward: Key Players and Industry Outlook

In the landscape of the Global Psychobiotics market, influential players such as InnovixLabs, Bened Biomedical Co., Ltd., Nutrimmun GmbH, Kerry Group PLC, Sabinsa Corporation, Lallemand Health Solutions Inc., DuPont de Nemours, Inc., Uplift Food Pty. Ltd., Nature’s Bounty Co. Ltd., BioGaia Group, The Life Extension Foundation, and Lifted Naturals are at the forefront. Their endeavors to develop innovative psychobiotic offerings and align with evolving consumer preferences position them as catalysts for the sector’s evolution.

Conclusion: A Promising Future for Psychobiotics

The forecasted growth of the Global Psychobiotics market between 2024 and 2028 is a testament to the profound impact of mental health concerns on global populations. The emergence of psychobiotics as a transformative solution, along with the heightened awareness of probiotics’ potential, are shaping the trajectory of mental health management.

Report Scope

In this report, global psychobiotics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Psychotropic Agent

• Streptococcus
• Bifidobacterium
• Lactobacillus
• Clostridium
• Others

Form

• Powder
• Liquid/Fluid
• Tablets
• Others

Application

• Stress Management
• Mood Health & Mood Upliftment
• Depression
• Anxiety
• Sleep Problems
• Others

Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Key Topics Covered

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Clinical Trial Analysis

6. Patents Analysis

7. Global Psychobiotics Market Outlook

8. North America Psychobiotics Market Outlook

9. Europe Psychobiotics Market Outlook

10. Asia-Pacific Psychobiotics Market Outlook

11. South America Psychobiotics Market Outlook

12. Middle East and Africa Psychobiotics Market Outlook

13. Market Dynamics

14. Market Trends & Developments

15. Competitive Landscape

16. Strategic Recommendations

A selection of companies mentioned in this report includes:

• InnovixLabs
• Bened Biomedical Co. Ltd.
• Nutrimmun GmbH
• Kerry Group PLC
• Sabinsa Corporation
• Lallemand Health Solutions Inc.
• DuPont de Nemours, Inc.
• Uplift Food Pty. Ltd.
• Nature’s Bounty Co. Ltd.
• BioGaia Group
• The Life Extension Foundation
• Lifted Naturals

For more information about this report visit https://www.researchandmarkets.com/r/bqd5so

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900